OUR
APPROACH
Our company is purpose built to treat
the underlying cause of genetic disease.
Key elements
We utilize these key elements of our strategy to achieve this vision:
Focus our therapeutic candidates on genetic diseases of high unmet need and with substantial potential for societal impact and commercial opportunity, such as genetically defined cardiovascular and neurological diseases.
Advance a deep and diverse pipeline that includes candidates that are designed to address both rare and more prevalent patient populations, prioritizing conditions most likely to benefit from our therapies.
Pursue a staged, capital-efficient approach for advancing programs through clinical development and regulatory approval.
Utilize a unified, high-quality manufacturing platform that can quickly respond at scale to high-impact opportunities.
Pursue next-generation technologies that can enhance our capabilities and expand our impact on patients.
Leverage and expand upon our partnerships and exclusive licenses with world-class academic institutions.
Build a leading biotech company that advances transformative therapies for genetic diseases and selectively pursue strategic opportunities to maximize pipeline impact.